BCMA-targeted Immunotherapy for Multiple Myeloma

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2020 Sep 18

PMID 32943087

Citations 93

Authors

Bo Yu

Tianbo Jiang

Delong Liu

Affiliations

Soon will be listed here.

Abstract

B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have achieved remarkable clinical response in patients with relapsed and refractory MM. Belantamab mafodotin-blmf (GSK2857916), a BCMA-targeted ADC, has just been approved for highly refractory MM. In this article, we summarized the molecular and physiological properties of BCMA as well as BCMA-targeted immunotherapeutic agents in different stages of clinical development.

Citing Articles

BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting.

Zheng H, Xian H, Zhang W, Lu C, Pan R, Liu H J Hematol Oncol. 2025; 18(1):23.

PMID: 40025529 PMC: 11872297. DOI: 10.1186/s13045-025-01675-5.

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment.

Navab R, Futela P, Kumari V, Valecha J, Gupta R, Jain R Iran J Med Sci. 2025; 50(1):1-10.

PMID: 39957814 PMC: 11829063. DOI: 10.30476/ijms.2024.101739.3446.

Natural killer cell engagers for cancer immunotherapy.

Nikkhoi S, Li G, Hatefi A Front Oncol. 2025; 14:1483884.

PMID: 39911822 PMC: 11794116. DOI: 10.3389/fonc.2024.1483884.

Targeting BCMA in multiple myeloma: designs, challenges, and future directions.

Hu Y, Xie Y, Wang X, Yang L, Geng H, Yi Z Cancer Immunol Immunother. 2025; 74(3):77.

PMID: 39891674 PMC: 11787132. DOI: 10.1007/s00262-024-03913-0.

iPSC Technology Revolutionizes CAR-T Cell Therapy for Cancer Treatment.

Zong J, Li Y Bioengineering (Basel). 2025; 12(1).

PMID: 39851334 PMC: 11763340. DOI: 10.3390/bioengineering12010060.

References

Bellucci R, Alyea E, Chiaretti S, Wu C, Zorn E, Weller E . Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood. 2005; 105(10):3945-50. PMC: 1895080. DOI: 10.1182/blood-2004-11-4463. View

Matthes T, McKee T, Dunand-Sauthier I, Manfroi B, Park S, Passweg J . Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow. Leukemia. 2015; 29(9):1901-8. DOI: 10.1038/leu.2015.68. View

Neelapu S, Tummala S, Kebriaei P, Wierda W, Locke F, Lin Y . Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol. 2018; 15(4):218. PMC: 6716606. DOI: 10.1038/nrclinonc.2018.20. View

Tai Y, Mayes P, Acharya C, Zhong M, Cea M, Cagnetta A . Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014; 123(20):3128-38. PMC: 4023420. DOI: 10.1182/blood-2013-10-535088. View

Aujla A, Aujla R, Liu D . Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomark Res. 2019; 7:9. PMC: 6458768. DOI: 10.1186/s40364-019-0160-4. View

Usmani S, Ahmadi T, Ng Y, Lam A, Desai A, Potluri R . Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD. Oncologist. 2016; 21(11):1355-1361. PMC: 5189616. DOI: 10.1634/theoncologist.2016-0104. View

Darce J, Arendt B, Wu X, Jelinek D . Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol. 2007; 179(11):7276-86. DOI: 10.4049/jimmunol.179.11.7276. View

Nie Y, Lu W, Chen D, Tu H, Guo Z, Zhou X . Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies. Biomark Res. 2020; 8:18. PMC: 7254656. DOI: 10.1186/s40364-020-00197-1. View

Claudio J, Masih-Khan E, Tang H, Goncalves J, Voralia M, Li Z . A molecular compendium of genes expressed in multiple myeloma. Blood. 2002; 100(6):2175-86. DOI: 10.1182/blood-2002-01-0008. View

10.

Sanchez E, Li M, Kitto A, Li J, Wang C, Kirk D . Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012; 158(6):727-38. DOI: 10.1111/j.1365-2141.2012.09241.x. View

11.

Wu C, Zhang L, Brockman Q, Zhan F, Chen L . Chimeric antigen receptor T cell therapies for multiple myeloma. J Hematol Oncol. 2019; 12(1):120. PMC: 6873434. DOI: 10.1186/s13045-019-0823-5. View

12.

Jiang H, Zhang W, Shang P, Zhang H, Fu W, Ye F . Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol. 2014; 8(2):297-310. PMC: 5528539. DOI: 10.1016/j.molonc.2013.12.001. View

13.

Xu J, Wang Q, Xu H, Gu C, Jiang L, Wang J . Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma. J Hematol Oncol. 2018; 11(1):128. PMC: 6198365. DOI: 10.1186/s13045-018-0672-7. View

14.

Ghermezi M, Li M, Vardanyan S, Harutyunyan N, Gottlieb J, Berenson A . Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2016; 102(4):785-795. PMC: 5395119. DOI: 10.3324/haematol.2016.150896. View

15.

Madry C, Laabi Y, Callebaut I, Roussel J, Hatzoglou A, Le Coniat M . The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily. Int Immunol. 1998; 10(11):1693-702. DOI: 10.1093/intimm/10.11.1693. View

16.

Zhao J, Song Y, Liu D . Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. J Hematol Oncol. 2019; 12(1):17. PMC: 6376657. DOI: 10.1186/s13045-019-0705-x. View

17.

Kantarjian H, Stein A, Gokbuget N, Fielding A, Schuh A, Ribera J . Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017; 376(9):836-847. PMC: 5881572. DOI: 10.1056/NEJMoa1609783. View

18.

Jia H, Wang Z, Wang Y, Liu Y, Dai H, Tong C . Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation. J Hematol Oncol. 2019; 12(1):57. PMC: 6558895. DOI: 10.1186/s13045-019-0741-6. View

19.

Liu D, Zhao J, Song Y . Engineering switchable and programmable universal CARs for CAR T therapy. J Hematol Oncol. 2019; 12(1):69. PMC: 6610960. DOI: 10.1186/s13045-019-0763-0. View

20.

Zhou L, Schwarting R, Smith H, Tedder T . A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily. J Immunol. 1992; 149(2):735-42. View